Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set

Bykerk, Vivian P, Bingham, Clifton O, Choy, Ernest H. ORCID: https://orcid.org/0000-0003-4459-8609, Lin, Daming, Alten, Rieke, Christensen, Robin, Furst, Daniel E, Hewlett, Sarah, Leong, Amye, March, Lyn, Woodworth, Thasia, Boire, Gilles, Haraoui, Boulos, Hitchon, Carol, Jamal, Shahin, Keystone, Edward C, Pope, Janet, Tin, Diane, Thorne, J Carter and Bartlett, Susan J 2016. Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set. RMD Open 2 (1) , e000225. 10.1136/rmdopen-2015-000225

Preview

PDF - Published Version Download (472kB) | Preview

Abstract

Objective To evaluate the reliability of concurrent flare identification using 3 methods (patient, rheumatologist and Disease Activity Score (DAS)28 criteria), and construct validity of candidate items representing the Outcome Measures in Rheumatology Clinical Trials (OMERACT) RA Flare Core Domain Set. Methods Candidate flare questions and legacy measures were administered at consecutive visits to Canadian Early Arthritis Cohort (CATCH) patients between November 2011 and November 2014. The American College of Rheumatology (ACR) core set indicators were recorded. Concordance to identify flares was assessed using the agreement coefficient. Construct validity of flare questions was examined: convergent (Spearman's r); discriminant (mean differences between flaring/non-flaring patients); and consequential (proportions with prior treatment reductions and intended therapeutic change postflare). Results The 849 patients were 75% female, 81% white, 42% were in remission/low disease activity (R/LDA), and 16–32% were flaring at the second visit. Agreement of flare status was low–strong (κ's 0.17–0.88) and inversely related to RA disease activity level. Flare domains correlated highly (r's≥0.70) with each other, patient global (r's≥0.66) and corresponding measures (r's 0.49–0.92); and moderately highly with MD and patient-reported joint counts (r's 0.29–0.62). When MD/patients agreed the patient was flaring, mean flare domain between-group differences were 2.1–3.0; 36% had treatment reductions prior to flare, with escalation planned in 61%. Conclusions Flares are common in rheumatoid arthritis (RA) and are often preceded by treatment reductions. Patient/MD/DAS agreement of flare status is highest in patients worsening from R/LDA. OMERACT RA flare questions can discriminate between patients with/without flare and have strong evidence of construct and consequential validity. Ongoing work will identify optimal scoring and cut points to identify RA flares.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Medicine
Publisher:	BMJ Publishing Group
ISSN:	2056-5933
Date of First Compliant Deposit:	12 July 2017
Date of Acceptance:	22 April 2016
Last Modified:	03 May 2023 14:33
URI:	https://orca.cardiff.ac.uk/id/eprint/102325

Citation Data

Cited 42 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item